Difference between revisions of "Cabozantinib (Cometriq)"
Jump to navigation
Jump to search
(added clinical trials) |
|||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Small molecule that inhibits multiple tyrosine kinases: MET, VEGFR2, RET, and KIT.<ref>[http://www.exelixis.com/cabozantinib Exelixis site for cabozantinib]</ref><ref>[http://www.exelixis.com/cabozantinib/clinical-trial-information Clinical trials]</ref> | + | Class/mechanism: Small molecule that inhibits multiple tyrosine kinases: MET/c-Met, VEGFR2, RET, and KIT.<ref>[http://www.exelixis.com/cabozantinib Exelixis site for cabozantinib]</ref><ref>[http://www.exelixis.com/cabozantinib/clinical-trial-information Clinical trials]</ref> |
| − | <br>Route: | + | <br>Route: PO |
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information. |
| + | |||
| + | ==Clinical trials== | ||
| + | *[http://clinicaltrials.gov/ct2/show/NCT00940225 Study of Cabozantinib (XL184) in Adults With Advanced Malignancies] | ||
| + | *[http://clinicaltrials.gov/ct2/show/NCT00960492 Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma] | ||
| + | *[http://clinicaltrials.gov/ct2/show/NCT00596648 A Study of XL184 (Cabozantinib) With or Without Erlotinib in Adults With Non-Small Cell Lung Cancer] | ||
| + | *[http://clinicaltrials.gov/ct2/show/NCT00704730 Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer (EXAM)] | ||
| + | *[http://clinicaltrials.gov/ct2/show/NCT01100619 A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors] | ||
| + | *[http://clinicaltrials.gov/ct2/show/NCT00704288 Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme] | ||
| + | *[http://clinicaltrials.gov/ct2/show/NCT01347788 Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer] | ||
| + | *[http://clinicaltrials.gov/ct2/show/NCT01574937 XL-184+Abiraterone in Post-Chemo CRPC] | ||
| + | *[http://clinicaltrials.gov/ct2/show/NCT01428219 Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone] | ||
| + | *[http://clinicaltrials.gov/ct2/show/NCT01522443 Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer (COMET-2)] | ||
| + | |||
==Patient drug information== | ==Patient drug information== | ||
| − | + | No information available. | |
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 22:06, 25 April 2012
General information
Class/mechanism: Small molecule that inhibits multiple tyrosine kinases: MET/c-Met, VEGFR2, RET, and KIT.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Clinical trials
- Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
- Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma
- A Study of XL184 (Cabozantinib) With or Without Erlotinib in Adults With Non-Small Cell Lung Cancer
- Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer (EXAM)
- A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors
- Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme
- Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer
- XL-184+Abiraterone in Post-Chemo CRPC
- Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone
- Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer (COMET-2)
Patient drug information
No information available.